NASDAQ:DVAX Dynavax Technologies (DVAX) Stock Price, News & Analysis → The asset beating inflation by 4x (From Colonial Metals) (Ad) Free DVAX Stock Alerts $11.74 +0.02 (+0.17%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$11.71▼$12.0650-Day Range$11.17▼$13.1452-Week Range$10.57▼$15.15Volume1.82 million shsAverage Volume2.12 million shsMarket Capitalization$1.54 billionP/E RatioN/ADividend YieldN/APrice Target$25.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Dynavax Technologies alerts: Email Address Dynavax Technologies MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside112.9% Upside$25.00 Price TargetShort InterestBearish14.17% of Shares Sold ShortDividend StrengthN/ASustainability-1.59Upright™ Environmental ScoreNews Sentiment-0.17Based on 2 Articles This WeekInsider TradingSelling Shares$262,322 Sold Last QuarterProj. Earnings Growth79.17%From $0.24 to $0.43 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.13 out of 5 starsMedical Sector895th out of 5,424 stocksPharmaceutical Preparations Industry307th out of 2,538 stocks 3.4 Analyst's Opinion Consensus RatingDynavax Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDynavax Technologies has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.17% of the outstanding shares of Dynavax Technologies have been sold short.Short Interest Ratio / Days to CoverDynavax Technologies has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Dynavax Technologies has recently increased by 3.17%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldDynavax Technologies does not currently pay a dividend.Dividend GrowthDynavax Technologies does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDynavax Technologies has received a 74.16% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Hepatitis B vaccines", "Clinical research services for infectious diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Dynavax Technologies is -1.59. Previous Next 1.0 News and Social Media Coverage News SentimentDynavax Technologies has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Dynavax Technologies this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for DVAX on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Dynavax Technologies to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dynavax Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $262,322.00 in company stock.Percentage Held by InsidersOnly 2.98% of the stock of Dynavax Technologies is held by insiders.Percentage Held by Institutions96.96% of the stock of Dynavax Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Dynavax Technologies are expected to grow by 79.17% in the coming year, from $0.24 to $0.43 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dynavax Technologies is -195.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dynavax Technologies is -195.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDynavax Technologies has a P/B Ratio of 2.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About Dynavax Technologies Stock (NASDAQ:DVAX)Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.Read More DVAX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DVAX Stock News HeadlinesApril 30, 2024 | markets.businessinsider.comBiotech Stocks Facing FDA Decision In May 2024April 26, 2024 | americanbankingnews.comDynavax Technologies (NASDAQ:DVAX) Lowered to Hold at StockNews.comMay 4, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...April 24, 2024 | finance.yahoo.comDynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024April 9, 2024 | stocknews.com3 Biotech Buys Under $15March 25, 2024 | finance.yahoo.comThose who invested in Dynavax Technologies (NASDAQ:DVAX) five years ago are up 68%March 24, 2024 | seekingalpha.comDynavax Technologies: Still A BelieverMarch 24, 2024 | seekingalpha.comDynavax Technologies: Still A BelieverMay 4, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...March 23, 2024 | seekingalpha.comDynavax: Holding Firm Despite Its Missing Cash CowMarch 23, 2024 | seekingalpha.comDynavax: Holding Firm Despite Its Missing Cash CowMarch 15, 2024 | bizjournals.comHow vaccine maker Dynavax tested itself and found a corporate cureMarch 14, 2024 | forbes.comDynavax CFO Kelly MacDonald: Making An Impact In The Biotech IndustryMarch 10, 2024 | uk.finance.yahoo.comDynavax Technologies Corporation (DVAX)March 5, 2024 | finance.yahoo.comChief Accounting Officer Justin Burgess Sells Shares of Dynavax Technologies Corp (DVAX)February 27, 2024 | finance.yahoo.comDynavax Technologies Corp (DYF1.DU)February 27, 2024 | prnewswire.comDynavax to Present at TD Cowen's 44th Annual Health Care ConferenceFebruary 24, 2024 | msn.comDynavax GAAP EPS of $0.00 beats by $0.01, revenue of $55.6M beats by $2.87MFebruary 24, 2024 | markets.businessinsider.comDynavax’s Strong Financials and Promising Pipeline Secure Buy RatingFebruary 23, 2024 | markets.businessinsider.comDynavax’s Strong Financial Outlook and Heplisav-B Market Expansion Prompt ‘Buy’ RatingFebruary 23, 2024 | finance.yahoo.comDynavax Technologies Corporation (NASDAQ:DVAX) Q4 2023 Earnings Call TranscriptFebruary 23, 2024 | finanznachrichten.deDynavax Technologies: Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial GuidanceFebruary 22, 2024 | benzinga.comDynavax Technologies: Q4 Earnings InsightsFebruary 22, 2024 | finance.yahoo.comDynavax Technologies Corp (DVAX) Reports Robust Revenue Growth and Market Leadership in 2023February 22, 2024 | fool.comDynavax Technologies (DVAX) Q4 2023 Earnings Call TranscriptFebruary 22, 2024 | seekingalpha.comDynavax Technologies Corporation 2023 Q4 - Results - Earnings Call PresentationFebruary 22, 2024 | prnewswire.comDynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial GuidanceSee More Headlines Receive DVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today5/04/2024Next Earnings (Confirmed)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:DVAX CUSIP26815810 CIK1029142 Webwww.dynavax.com Phone(510) 848-5100Fax510-848-1327Employees408Year Founded1996Price Target and Rating Average Stock Price Target$25.00 High Stock Price Target$28.00 Low Stock Price Target$20.00 Potential Upside/Downside+112.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.06) Trailing P/E RatioN/A Forward P/E Ratio48.92 P/E GrowthN/ANet Income$-6,390,000.00 Net Margins-2.75% Pretax Margin-1.88% Return on Equity-1.08% Return on Assets-0.66% Debt Debt-to-Equity Ratio0.41 Current Ratio13.81 Quick Ratio12.96 Sales & Book Value Annual Sales$232.28 million Price / Sales6.61 Cash FlowN/A Price / Cash FlowN/A Book Value$4.81 per share Price / Book2.44Miscellaneous Outstanding Shares130,860,000Free Float126,963,000Market Cap$1.54 billion OptionableOptionable Beta1.30 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Ryan Spencer (Age 46)CEO, Interim CFO & Director Comp: $1.49MMr. David F. Novack (Age 62)President & COO Comp: $1.01MDr. Robert Janssen M.D. (Age 70)Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs Comp: $861.52kMs. Kelly MacDonald (Age 40)Senior VP & CFO (Leave of Absence) Comp: $788.55kMr. Justin BurgessChief Accounting Officer & ControllerMr. Jeff P. Coon (Age 61)Senior VP & Chief Human Resources Officer Mr. Paul CoxVP of Investor Relations & Corporate CommunicationsMr. John L. Slebir (Age 58)Senior VP & General Counsel Mr. Donn CasaleSenior VP & Chief Commercial OfficerDr. Dong YuSenior Vice President of Vaccine ResearchMore ExecutivesKey CompetitorsLigand PharmaceuticalsNASDAQ:LGNDIronwood PharmaceuticalsNASDAQ:IRWDMannKindNASDAQ:MNKDProthenaNASDAQ:PRTAOPKO HealthNASDAQ:OPKView All CompetitorsInsiders & InstitutionsEssex Investment Management Co. LLCBought 278,764 shares on 5/3/2024Ownership: 0.308%Nordea Investment Management ABBought 73,681 shares on 5/2/2024Ownership: 0.301%BNP Paribas Financial MarketsSold 110,937 shares on 5/1/2024Ownership: 0.231%Mirae Asset Global Investments Co. Ltd.Sold 7,466 shares on 5/1/2024Ownership: 0.061%China Universal Asset Management Co. Ltd.Bought 10,143 shares on 4/29/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions DVAX Stock Analysis - Frequently Asked Questions Should I buy or sell Dynavax Technologies stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DVAX shares. View DVAX analyst ratings or view top-rated stocks. What is Dynavax Technologies' stock price target for 2024? 4 brokers have issued 1-year target prices for Dynavax Technologies' shares. Their DVAX share price targets range from $20.00 to $28.00. On average, they anticipate the company's share price to reach $25.00 in the next twelve months. This suggests a possible upside of 112.9% from the stock's current price. View analysts price targets for DVAX or view top-rated stocks among Wall Street analysts. How have DVAX shares performed in 2024? Dynavax Technologies' stock was trading at $13.98 at the start of the year. Since then, DVAX stock has decreased by 16.0% and is now trading at $11.74. View the best growth stocks for 2024 here. When is Dynavax Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our DVAX earnings forecast. How can I listen to Dynavax Technologies' earnings call? Dynavax Technologies will be holding an earnings conference call on Wednesday, May 8th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Dynavax Technologies' earnings last quarter? Dynavax Technologies Co. (NASDAQ:DVAX) issued its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by $0.29. The biopharmaceutical company earned $108.27 million during the quarter, compared to analyst estimates of $77.30 million. Dynavax Technologies had a negative net margin of 2.75% and a negative trailing twelve-month return on equity of 1.08%. During the same period in the prior year, the business earned ($0.15) EPS. What ETFs hold Dynavax Technologies' stock? ETFs with the largest weight of Dynavax Technologies (NASDAQ:DVAX) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Biotechnology & Genome ETF (PBE), iShares Genomics Immunology and Healthcare ETF (IDNA), Invesco S&P SmallCap Health Care ETF (PSCH) and SPDR S&P Biotech ETF (XBI).Direxion Daily S&P Biotech Bull 3x Shares (LABU). What is Eddie Gray's approval rating as Dynavax Technologies' CEO? 13 employees have rated Dynavax Technologies Chief Executive Officer Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among the company's employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 61.0% of employees surveyed would recommend working at Dynavax Technologies to a friend. What other stocks do shareholders of Dynavax Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA). Who are Dynavax Technologies' major shareholders? Dynavax Technologies' stock is owned by a variety of institutional and retail investors. Top institutional investors include Principal Financial Group Inc. (0.59%), Essex Investment Management Co. LLC (0.31%), Nordea Investment Management AB (0.30%), BNP Paribas Financial Markets (0.23%), Congress Asset Management Co. MA (0.18%) and Allspring Global Investments Holdings LLC (0.11%). Insiders that own company stock include Andrew A F Hack, David F Novack, David F Novack, Francis Cano, Justin Burgess, Robert Janssen and Ryan Spencer. View institutional ownership trends. How do I buy shares of Dynavax Technologies? Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DVAX) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchCould Your Accounts Be Frozen?Allegiance GoldFW: 234x GainWeiss RatingsThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dynavax Technologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.